Medical Condition News

RSS

Implications for reducing clotting in kidney disease dialysis and sepsis

The interaction of the drug compstatin with two ancient, co-evolved human systems points to new ways for reducing clotting during dialysis for end-stage kidney disease and multiple organ failure due to sepsis, a dangerous whole-body inflammatory response to infection.

17 Jun 2010

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA® (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The results will be presented today in Rome at the 2010 Congress of the European League Against Rheumatism (EULAR).

17 Jun 2010

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

17 Jun 2010

Patients prescribed NSAIDs also receive appropriate measures to prevent UGI problems: Study

Four out of ten high-risk patients prescribed nonsteroidal anti-inflammatory drugs also received appropriate measures to prevent upper-gastrointestinal problems, but the remainder did not receive adequate protection, according to a study in the June issue of Alimentary Pharmacology and Therapeutics.

17 Jun 2010

Excess neuronal protein plays role in the evolution of neurodegenerative diseases: Research

In diverse neurodegenerative diseases ranging from Parkinson's to Alzheimer's, researchers have long noted accumulations of a little-understood neuronal protein called α-synuclein. Pathological and genetic evidence strongly suggested that excessive α-synuclein played a role in the evolution of these diseases, but it was unclear how too much α-synuclein culminated in synaptic damage and neurodegeneration.

17 Jun 2010

USFDA approves Sun Pharma's generic Keppra Injection ANDA

Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Keppra® Injection, levetiracetam injection.

17 Jun 2010

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

A research team from McGill University (Canada) report a beneficial effect on cardiac function in mouse models when implanted monocytes - a type of white blood cell that is part of the immune system - helped preserve cardiac function following a heart attack (myocardial infarction).

17 Jun 2010

Researchers identify peptide that triggers diabetes

Researchers at National Jewish Health and the University of Colorado Anschutz Medical Campus have identified the precise protein fragment, or peptide, that can trigger diabetes in mice. The finding, published in the June 15, 2010, issue of the Proceedings of the National Academy of Sciences, supports an emerging theory about the origins of autoimmunity, and may lead to new diagnostic and therapeutic strategies in humans.

17 Jun 2010

Alzheimer's disease may damage brain

Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.

17 Jun 2010

Deuterium depletion symposium focusses on oncotherapy, anticancer, diabetes, anti-aging research

1st International Symposium on Deuterium Depletion was held on 13-14 May 2010 in Budapest, Hungary. The conference programme focused on the advances in the research and clinical application of deuterium depletion, its present and future role in anticancer research and oncotherapy, diabetes research and anti-aging.

17 Jun 2010

Research studies may lead to future development of cell transplant therapy for ALS

The University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies Corporation today announced the initiation of studies which may lead to the future development of cell transplant therapy for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Currently, there is only one FDA-approved pharmaceutical addressing this lethal disease, which affects approximately 30,000 people in the United States.

17 Jun 2010

Symposium explores new understanding of mitochondrial function, cellular bioenergetics in cancer research

Seahorse Bioscience, Inc., the leader in instruments for assessing cellular bioenergetics, recently organized a symposium on Cancer and Mitochondrial Function featuring Douglas Green, Ph.D., from St. Jude Children's Hospital; Navdeep S. Chandel, Ph.D., from Northwestern Medical School; and Nicholas C. Denko, Ph.D., from Stanford University School of Medicine.

17 Jun 2010

Researchers use computer-based model to study human visual intelligence

Scientists have just come several steps closer to understanding change blindness - the well studied failure of humans to detect seemingly obvious changes to scenes around them - with new research that used a computer-based model to predict what types of changes people are more likely to notice.

17 Jun 2010

Micrus Endovascular receives approval to market DeltaPaq, DeltaPlush microcoils for cerebral aneurysms in Japan

Micrus Endovascular Corporation today announced receipt of Shonin approval from the Ministry of Health, Labour and Welfare to market in Japan its novel bare platinum and Cerecyte® DeltaPaq™ filling and DeltaPlush™ finishing microcoils for the treatment of cerebral aneurysms and treatments in the peripheral vasculature.

17 Jun 2010

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, Germany, today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer.

17 Jun 2010

Ipsen, Inspiration receive positive opinion in Europe for orphan drug status of OBI-1 in treatment of hemophilia

Ipsen and Inspiration Biopharmaceuticals, Inc. announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency has issued a positive opinion on the granting of orphan drug status for OBI-1 for the treatment of hemophilia.

17 Jun 2010

Gabapentin shows effective in patients with locked-in syndrome, opsoclonus-myoclonus syndrome

For patients with quadriplegia, mutism and lower cranial nerve paralysis (locked-in syndrome), their only means of interacting with others is through vertical gaze and upper eyelid movements, using eye-coded communication strategies.

17 Jun 2010

Pan-Canadian Cancer Research Strategy to maximize impact of cancer research funding

A new strategy to help coordinate cancer research investment across Canada will enable the country's cancer research funders to make faster progress on shared priorities and maximize the impact of cancer research funding in Canada - in turn enabling more Canadians to benefit from new discoveries.

17 Jun 2010

Positive results from Cytomedix's AutoloGel System study for treatment of advanced, chronic wounds published

Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that positive results from a prospective study evaluating the AutoloGel™ System to treat advanced, chronic wounds was published in the June 2010 issue of Ostomy Wound Management in a peer reviewed article entitled, "Chronic Wounds Treated With a Physiologically Relevant Concentration of Platelet-rich Plasma (PRP) Gel: A Prospective Case Series."

17 Jun 2010

Stimuvax clinical program resumed in patients with NSCLC

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that they are resuming their Stimuvax (BLP25 liposome vaccine) clinical program in patients with non-small cell lung cancer which includes the Phase III studies, START and INSPIRE. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees.

17 Jun 2010

Medical Condition News

Implications for reducing clotting in kidney disease dialysis and sepsis

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Patients prescribed NSAIDs also receive appropriate measures to prevent UGI problems: Study

Excess neuronal protein plays role in the evolution of neurodegenerative diseases: Research

USFDA approves Sun Pharma's generic Keppra Injection ANDA

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

Researchers identify peptide that triggers diabetes

Alzheimer's disease may damage brain

Deuterium depletion symposium focusses on oncotherapy, anticancer, diabetes, anti-aging research

Research studies may lead to future development of cell transplant therapy for ALS

Symposium explores new understanding of mitochondrial function, cellular bioenergetics in cancer research

Researchers use computer-based model to study human visual intelligence

Micrus Endovascular receives approval to market DeltaPaq, DeltaPlush microcoils for cerebral aneurysms in Japan

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

Ipsen, Inspiration receive positive opinion in Europe for orphan drug status of OBI-1 in treatment of hemophilia

Gabapentin shows effective in patients with locked-in syndrome, opsoclonus-myoclonus syndrome

Pan-Canadian Cancer Research Strategy to maximize impact of cancer research funding

Positive results from Cytomedix's AutoloGel System study for treatment of advanced, chronic wounds published

Stimuvax clinical program resumed in patients with NSCLC

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Latest News